应用虚拟现实(Virtual reality, VR)平台评估眼科视觉质量及其应用研究:主视眼、模拟同视机与视野仪等

注册号:

Registration number:

ChiCTR1800014332 

最近更新日期:

Date of Last Refreshed on:

2018-01-06 11:41:46 

注册时间:

Date of Registration:

2018-01-06 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

应用虚拟现实(Virtual reality, VR)平台评估眼科视觉质量及其应用研究:主视眼、模拟同视机与视野仪等

Public title:

The evaluation of a new techqnique application: The imitation of ocular dominance test, synoptophore and visual field analyser by Virtual Reality (VR)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

应用虚拟现实(Virtual reality, VR)平台评估眼科视觉质量及其应用研究:主视眼、模拟同视机与视野仪等

Scientific title:

The evaluation of a new techqnique application: The imitation of ocular dominance test, synoptophore and visual field analyser by Virtual Reality (VR)

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

余威德 

研究负责人:

余威德 

Applicant:

YU WEIDE 

Study leader:

YU WEIDE 

申请注册联系人电话:

Applicant telephone:

+86 13957835133

研究负责人电话:

Study leader's
telephone:

+86 13957835133

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

johnywd@vip.qq.com

研究负责人电子邮件:

Study leader's E-mail:

johnywd@vip.qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省宁波市第一医院眼科中心柳汀街59号

研究负责人通讯地址:

浙江省宁波市第一医院眼科中心柳汀街59号

Applicant address:

59 Liuting Street, Ningbo, Zhejiang, China

Study leader's address:

59 Liuting Street, Ningbo, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

315010

研究负责人邮政编码:

Study leader's postcode:

315010

申请人所在单位:

宁波市第一医院

Applicant's institution:

Eye Center, Ningbo First Hospital

研究负责人所在单位:

宁波市第一医院

Affiliation of the Leader:

Ningbo First Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2017-R012

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宁波市第一医院医学伦理委员会

Name of the ethic committee:

IRB of Ningbo First Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2017-07-11 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

宁波市第一医院

Primary sponsor:

Ningbo First Hospital

研究实施负责(组长)单位地址:

浙江省宁波市第一医院眼科中心柳汀街59号

Primary sponsor's address:

59 Liuting Street, Ningbo, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

宁波市

Country:

China

Province:

Zhejiang

City:

Ningbo City

单位(医院):

宁波市第一医院

具体地址:

浙江省宁波市第一医院眼科中心柳汀街59号

Institution
hospital:

Ningbo First Hospital

Address:

59 Liuting Street, Ningbo, Zhejiang, China

经费或物资来源:

宁波第一医院以及政府的补助金

Source(s) of funding:

Ningbo First Hospital and government grants

研究疾病:

视光学疾病  

Target disease:

Visual disease

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

诊断试验新技术临床试验 

Study phase:

Diagnostic New Technique Clincal Study

研究设计:

诊断性病例对照试验 

Study design:

Diagnostic test: case-control 

研究目的:

本研究应用虚拟现实(Virtual Reality,VR)设备为视觉测试平台,来模拟传统眼科设备的同视机功能,视野仪,主视眼的功能,并且进行初步的对照研究。  

Objectives of Study:

In this study, the Virtual Reality (VR) equipment is used as the platform for visual functions, simulate the functions of synoptophore, visual field perimeter and ocular dominance test procedure, these traditional ophthalmic equipments will be compared with VR for initial controlled study.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.严重的斜视患者, 不透明的眼角膜或晶状体,视网膜疾病,精神疾病患者。
2.检查无法配合者。

Exclusion criteria:

1. Severe strabismus, opaque cornea or crystalline lens, retinal disease, and psychiatric patients;
2. The subjectives who can not cooperate with the examinations.

研究实施时间:

Study execute time:

From 2017-07-15 00:00:00 To 2019-07-16 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-07-15 00:00:00 To 2019-07-16 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

传统同视机,视野仪,主视眼测试

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Traditional synoptophore, visual field perimeter and ocular dominance measures.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

VR模拟同视机,视野仪,主视眼

Index test:

Virtual reality synoptophore, visual field perimeter and ocular dominance test.

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

拟接受超声乳化联合人工晶状体(IOL)植入手术治疗的白内障病患、斜视患者、青光眼或视野缺损相关性眼疾之病患

例数:

Sample size:

150

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

The phacoemulsification with intraocular lens (IOL) implantation for cataract surgery, strabismus, glaucoma and visual field defect disease patients.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

1.严重的斜视患者, 不透明的眼角膜或晶状体,视网膜疾病,精神疾病患者。 2.检查无法配合者。

例数:

Sample size:

150

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

1.Severe strabismus, opaque cornea or crystalline lens, retinal disease, and psychiatric patients. 2.The subjectivs whom can not cooperate with the examinations.

研究实施地点:

Countries of recruitment and research settings:

测量指标:

Outcomes:

指标中文名:

最佳矫正视力

指标类型:

主要指标

Outcome:

'best corrected visual acuity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视野

指标类型:

主要指标

Outcome:

Visual field

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视力

指标类型:

主要指标

Outcome:

visual acuity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

斜视度

指标类型:

主要指标

Outcome:

esotropia deviation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

生物数据

组织:

Sample Name:

biodata

Tissue:

none

人体标本去向

其它  

说明

none

Fate of sample:

0thers  

Note:

none

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 8 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

在研究中,样本的来源由门诊医师诊断为视觉光学相关疾病的患者。

Randomization Procedure (please state who generates the random number sequence and by what method):

In this study, the source of the samples are diagnosed by the physician from outpatient, such as a visual disease patient.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

医学研讨会会议文摘或期刊论文发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Medical seminar abstracts or journal papers published

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用病例记录表(Case Record Form, CRF)以及其他文书作业软件辅助记录(如微软Office Excel和Word)。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Use Case Record Form (CRF) and other office software to assist in recording (such as Microsoft Office Excel and Word).

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2018-01-06 11:41:46